Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Active, not recruiting · NCT04136353 · Registry updated 2026-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-05-06 | NCT04136353 |
7 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
93 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.